Price
431.5
+4.3%52W Range
Market Cap
₹4,327.19 Cr
Traded: ₹9.09 Cr (0.21%) 0.0x
Free Float: ₹806.16 Cr (1.13% of FF traded)
Volume · 60D trend
2.12 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | -- | -- | -- | +17.0% | -- |
| ROE | -- | -- | +13.0% | -- | -- | -- |
| Return | +27.0% | +14.0% | +15.0% | +18.0% | -- | Accelerating |
| Profit | -- | -- | -- | -- | +19.0% | -- |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 261 | 252 | 231 | 237 | 224 | 205 | 208 | 204 | 203 | 195 | 202 | 215 |
| Expenses | 214 | 205 | 198 | 199 | 190 | 179 | 174 | 166 | 167 | 161 | 165 | 176 |
| Operating Profit | 47 | 47 | 33 | 38 | 33 | 26 | 34 | 39 | 36 | 34 | 36 | 39 |
| OPM % | 18.0% | 19.0% | 14.0% | 16.0% | 15.0% | 13.0% | 16.0% | 19.0% | 18.0% | 18.0% | 18.0% | 18.0% |
| Other Income | 0 | -1 | 1 | 2 | 1 | 0 | 2 | 0 | 1 | 1 | 0 | 0 |
| Interest | 9 | 9 | 8 | 10 | 9 | 8 | 5 | 5 | 5 | 4 | 3 | 4 |
| Depreciation | 8 | 8 | 8 | 8 | 8 | 8 | 5 | 4 | 4 | 4 | 4 | 4 |
| Profit Before Tax | 30 | 29 | 18 | 23 | 17 | 11 | 26 | 29 | 28 | 27 | 30 | 31 |
| Tax % | 26.0% | 24.0% | 30.0% | 26.0% | 24.0% | 27.0% | 26.0% | 26.0% | 26.0% | 26.0% | 25.0% | 25.0% |
| Net Profit | 22 | 22 | 12 | 17 | 13 | 8 | 19 | 22 | 21 | 20 | 22 | 23 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 2.2 | 2.2 | 1.2 | 1.7 | 1.3 | 0.8 | 1.9 | 2.2 | 2.1 | 2.0 | 2.2 | 2.4 |
| Sales Growth (YoY) | 16.5% | 22.9% | 11.1% | 16.2% | 10.3% | 5.1% | 3.0% | -5.1% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 3.6% | 9.1% | -2.5% | 5.8% | 9.3% | -1.4% | 2.0% | 0.5% | 4.1% | -3.5% | -6.0% | -- |
| OP Growth (YoY) | 42.4% | 80.8% | -2.9% | -2.6% | -8.3% | -23.5% | -5.6% | 0.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 0.0% | 42.4% | -13.2% | 15.2% | 26.9% | -23.5% | -12.8% | 8.3% | 5.9% | -5.6% | -7.7% | -- |
| Profit Growth (YoY) | 71.0% | 184.0% | -36.0% | -23.0% | -37.0% | -62.0% | -13.0% | -6.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | 70.8% | 183.1% | -35.8% | -22.6% | -37.5% | -61.5% | -13.1% | -9.2% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 1.8% | 75.8% | -26.2% | 29.2% | 68.8% | -60.1% | -11.1% | 4.3% | 4.0% | -9.9% | -7.1% | -- |
| OP Margin | 18.0% | 18.6% | 14.3% | 16.0% | 14.7% | 12.7% | 16.4% | 19.1% | 17.7% | 17.4% | 17.8% | 18.1% |
| Net Margin | 8.4% | 8.7% | 5.2% | 7.2% | 5.8% | 3.9% | 9.1% | 10.8% | 10.3% | 10.3% | 10.9% | 10.7% |
| Material Cost % | 44.1% | 45.6% | 43.6% | 44.1% | 45.0% | 43.7% | 45.3% | 47.1% | 46.7% | 45.4% | 47.3% | 50.8% |
| Employee Cost % | 16.0% | 15.2% | 17.3% | 15.8% | 16.1% | 17.4% | 16.3% | 13.9% | 14.3% | 15.2% | 15.2% | 12.5% |
| P/S | 4.41 | 4.49 | 3.73 | 3.25 | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 58.95 | 65.97 | 66.90 | 49.83 | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 6.51 | 6.37 | 5.31 | 4.50 | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Written Transcript of Earnings Conference Call held on August 17, 2026 at 04:30 p.m. is attached herewith
Newspaper advertisement regarding Special Window for re-lodgement of transfer and dematerialization of physical shares is attached herewith
Intimation of Audio Recording of Earnings Conference Call held on August 17, 2026 at 04:30 p.m. is attached herewith
Newspaper Advertisement of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026 is attached herewith.
Investor Presentation for the Quarter ended June 30, 2026 is attached herewith
Approval for Incorporation of Subsidiary in the Philippines and Investment by way of Subscription to its Equity Share Capital is attached herewith.
Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2026 is attached herewith.
Outcome of the Board of Directors Meeting held on Friday, August 14, 2026 is attached herewith.
Newspaper Advertisement - Notice of 42nd Annual General Meeting of the Company and evoting details is attached herewith.
Business Responsibility and Sustainability Report for the Financial Year ended March 31, 2026, is attached herewith
Annual Report for the Financial Year 2025-2026 alongwith Notice of 42nd Annual General Meeting is attached herewith.
Intimation for book closure and record date for the purpose of 42nd Annual General Meeting and payment of final dividend for the financial year ended March 31, 2026
Intimation of 42nd Annual General Meeting, is attached herewith
Intimation of Earnings Conference Call scheduled to be held on August 17, 2026 is attached herewith
Gufic Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Newspaper Advertisement - Notice of the 42nd Annual General Meeting of the Company is attached herewith
Outcome of the Board of Directors Meeting held on Friday, July 31, 2026 is attached herewith
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026 is attached herewith
Newspaper Advertisement regarding Notice for transfer of equity shares to Investor Education and Protection Fund (IEPF) Authority is attached herewith
Intimation of closure of Trading Window for the quarter ended June 30, 2026 is attached herewith
Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of physical shares is attached herewith.
Written Transcript of Earnings Conference Call held on June 01, 2026 at 04:30 PM is attached herewith.
Corrigendum and Clarification to Intimation dated May 29, 2026 regarding Subscription to Shares of Saraswat Co-operative Bank Limited, is attached herewith
Corrigendum and Collaboration to Intimation dated May 29, 2026 regarding Subscription to Shares of Saraswat Co-operative Bank Limited is attached herewith
Intimation for Audio Recording of Earnings Conference Call held on June 01, 2026 at 04:30 p.m. has been attached herewith.
Newspaper Advertisement of Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2026 is attached herewith.
Investor Presentation is attached herewith
Intimation for Re-appointment of Cost Auditor and Appointment of Internal Auditor is attached herewith
Intimation under Regulation 30 of SEBI Listing Regulations - Further Investment in Saraswat Co-operative Bank Limited is attached herewith.
Intimation for recommendation of final dividend for the financial year 2025-2026 is attached herewith
Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026 is attached herewith
Outcome of the Board of Directors Meeting held on Friday, May 29, 2026 is attached herewith
Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026 is attached herewith
Intimation of Earnings Conference Call scheduled to be held on June 01, 2026 is attached herewith.
Gufic Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Audited Financial Results ....
Update on further investment in Selvax Pty Ltd. is attached herewith
Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of physical shares is attached herewith
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026 is attached herewith
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith
Intimation of closure of Trading Window for the quarter and financial year ended March 31, 2026 is attached herewith.
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith
Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of Physical Shares is attached herewith.
Written Transcript of Earnings Conference Call held on February 16, 2026 at 04:30 PM is attached herewith.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Audio Recording of the Earnings Conference Call ....
Newspaper advertisement of Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025 is attached herewith
Intimation of further investment in Selvax Pty Ltd. is attached herewith
Investor Presentation is attached herewith
Outcome of the Board of Directors Meeting held on Friday, February 13, 2026 is attached herewith
Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025 is attached herewith
Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to ....
Annual Reports
15Credit Ratings
6Concalls
24Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Jun 2024
30 Jun 2024May 2024
31 May 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021Jun 2021
30 Jun 2021Nov 2020
30 Nov 2020Held by ETFs
1 ETFs hold GUFICBIO · sorted by weight
Held by Mutual Funds
7 schemes hold GUFICBIO · sorted by weight